PL1725876T3 - Sposób przewidywania stanu śluzówki żołądka - Google Patents

Sposób przewidywania stanu śluzówki żołądka

Info

Publication number
PL1725876T3
PL1725876T3 PL05717315T PL05717315T PL1725876T3 PL 1725876 T3 PL1725876 T3 PL 1725876T3 PL 05717315 T PL05717315 T PL 05717315T PL 05717315 T PL05717315 T PL 05717315T PL 1725876 T3 PL1725876 T3 PL 1725876T3
Authority
PL
Poland
Prior art keywords
gastric mucosa
data
subject
state
predicting
Prior art date
Application number
PL05717315T
Other languages
English (en)
Inventor
Seppo Sarna
Tapani Tiusanen
Osmo Suovaniemi
Original Assignee
Biohit Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohit Oyj filed Critical Biohit Oyj
Publication of PL1725876T3 publication Critical patent/PL1725876T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
    • G01N2333/96475—Aspartic endopeptidases (3.4.23) with definite EC number
    • G01N2333/96477—Pepsin (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
PL05717315T 2004-03-05 2005-03-03 Sposób przewidywania stanu śluzówki żołądka PL1725876T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20040359A FI119572B (fi) 2004-03-05 2004-03-05 Menetelmä vatsan limakalvon tilan ennustamiseksi
PCT/FI2005/050061 WO2005085871A1 (en) 2004-03-05 2005-03-03 A method for predicting the state of the gastric mucosa
EP05717315A EP1725876B1 (en) 2004-03-05 2005-03-03 A method for predicting the state of the gastric mucosa

Publications (1)

Publication Number Publication Date
PL1725876T3 true PL1725876T3 (pl) 2009-10-30

Family

ID=32039385

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05717315T PL1725876T3 (pl) 2004-03-05 2005-03-03 Sposób przewidywania stanu śluzówki żołądka

Country Status (10)

Country Link
US (1) US20080162101A1 (pl)
EP (1) EP1725876B1 (pl)
JP (1) JP4814212B2 (pl)
CN (1) CN1950704A (pl)
AT (1) ATE430938T1 (pl)
DE (1) DE602005014345D1 (pl)
ES (1) ES2325170T3 (pl)
FI (1) FI119572B (pl)
PL (1) PL1725876T3 (pl)
WO (1) WO2005085871A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053537A1 (en) * 2007-10-26 2009-04-30 Biohit Oyj Methods and products for diagnosing autoimmune diseases and gastric cancer linked with atrophic gastritis
WO2011161301A1 (en) * 2010-06-24 2011-12-29 Valtion Teknillinen Tutkimuskeskus State inference in a heterogeneous system
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
EP3612843A1 (en) 2017-05-31 2020-02-26 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in crohn's disease patients
CN112002414B (zh) * 2020-08-23 2024-01-26 吾征智能技术(北京)有限公司 一种基于胃液认知胃病的系统、设备、存储介质
CN113466471B (zh) * 2021-09-06 2021-11-26 中国农业科学院农产品加工研究所 胃粘膜损伤相关生物标志物、筛选方法及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0746111B2 (ja) * 1988-03-18 1995-05-17 株式会社日立製作所 試料分析方法及びこれを用いた自動分析装置
US6861510B1 (en) * 1989-01-24 2005-03-01 Aphton Corporation Immunogenic compositions against gastrin peptides
FI97304C (fi) * 1994-11-16 1996-11-25 Locus Genex Oy Menetelmä mahasyövän riskin seulonnaksi
JP2949474B2 (ja) * 1995-08-28 1999-09-13 隆久 古田 ペプシノーゲンｉ／ｉｉ比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法
JP2000270897A (ja) * 1999-03-23 2000-10-03 Mitsubishi Kagaku Bio-Clinical Laboratories Inc トランスフォーミング増殖因子β１の遺伝子多型による骨粗鬆症危険因子の検出法
FI118653B (fi) * 1999-04-30 2008-01-31 Biohit Oyj Menetelmä peptisen haavan riskin määrittämiseksi
CA2404852A1 (en) * 2000-04-10 2001-10-18 Timothy C. Wang Diagnosis and treatment of gastrointestinal disease
FI20010019L (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
FI20011908L (fi) * 2001-09-28 2003-03-29 Biohit Oyj Menetelmä vatsasyövän osoittamiseksi
SE0200974D0 (sv) * 2002-03-27 2002-03-27 Phagen Ab Screening method for gastritis
FI119571B (fi) * 2002-09-06 2008-12-31 Biohit Oyj Menetelmä esofagiitin tai Barrettin ruokatorven riskin osoittamiseksi yksilöllä
US6950544B2 (en) * 2003-02-14 2005-09-27 Virtualscopics, Llc Automated measurement of anatomical structures in medical imaging

Also Published As

Publication number Publication date
ATE430938T1 (de) 2009-05-15
DE602005014345D1 (de) 2009-06-18
FI20040359L (fi) 2005-09-06
ES2325170T3 (es) 2009-08-27
EP1725876A1 (en) 2006-11-29
CN1950704A (zh) 2007-04-18
FI20040359A0 (fi) 2004-03-05
FI119572B (fi) 2008-12-31
EP1725876B1 (en) 2009-05-06
JP4814212B2 (ja) 2011-11-16
US20080162101A1 (en) 2008-07-03
WO2005085871A1 (en) 2005-09-15
JP2007526470A (ja) 2007-09-13

Similar Documents

Publication Publication Date Title
FI20010019A7 (fi) Menetelmä atrofisen gastriitin diagnostisoimiseksi
DE602004012974D1 (de) Abtastungverfahren und -vorrichtung zur abtastung von korrosion und oberflächenfehlern
NO20070611L (no) Resekvensering av patogene mikroarray.
WO2021076036A1 (en) Apparatuses and methods for detection of pancreatic cancer
WO2006126008A3 (en) Improved immunoassay methods
WO2005095644A3 (de) Verfahren zur erkennung von signaturen in komplexen genexpressionsprofilen
WO2010013138A3 (en) Methods and compositions for detection of a pathogen, disease, medical condition, or biomarker thereof
WO2007133586A3 (en) Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
Lefkowitz et al. An electrophoretic method for the detection of chymotrypsin and trypsin activity directly in whole blood
WO2020247952A2 (en) Systems comprising substrates and methods of using the same for detection of pancreatic cancers
PL1725876T3 (pl) Sposób przewidywania stanu śluzówki żołądka
WO2007126901A3 (en) Apparatus and method for predicting disease
Heers et al. VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach
AU2003260530A1 (en) Method for detecting a risk of acid related disease in an individual
ATE415623T1 (de) Verfahren und vorrichtung zur messung der aktivierung von neutrophilen zellen
WO2006092729A3 (en) Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
Miura et al. Analytical and Real‐World Clinical Characterization of S2, 3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population
RU2020127365A (ru) Способы, применения и комплекты для диагностики пародонтита
WO2003100079A3 (en) Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection
Hausfater et al. Prognostic value of PCT, copeptin, MR-proADM, MR-proANP and CT-proET-1 for severe acute dyspnea in the emergency department: the BIODINER study
WO2007056332A3 (en) Molecular diagnosis of autoimmune diseases
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
Suresh et al. A prototype assay multiplexing SARS-CoV-2 3CL-protease and angiotensin-converting enzyme 2 for saliva-based diagnostics in COVID-19